{"id":175,"date":"2019-01-29T15:51:19","date_gmt":"2019-01-29T06:51:19","guid":{"rendered":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol-test\/?page_id=175"},"modified":"2022-01-14T15:21:29","modified_gmt":"2022-01-14T06:21:29","slug":"publications2012","status":"publish","type":"page","link":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/publications\/publications2012\/","title":{"rendered":"2012"},"content":{"rendered":"

\u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09<\/strong><\/h4>\n
    \n
  1. \u6a0b\u7530\u4eac\u5b50<\/u>\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u3068\u764c\u306e\u60aa\u6027\u5316\u3068\u306e\u95a2\u9023\u3001\u65e5\u672c\u53e3\u8154\u816b\u760d\u5b66\u4f1a\u8a8c\u300124(3)\u300188-94\u30012012<\/li>\n
  2. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u3068\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3001\u201cDrug Delivery System\u201d\u3001\u7279\u96c6\uff62\u57fa\u790e\u304b\u3089\u62d3\u304fDDS\u5275\u85ac\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\uff63\u65e5\u672cDDS\u5b66\u4f1a\u300127(1)\u300134-39\u30012012<\/li>\n
  3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u3001\u300c\u751f\u5316\u5b66\u300d\u3001\u793e\u56e3\u6cd5\u4eba\u65e5\u672c\u751f\u5316\u5b66\u4f1a\u300184(1)\u300143-46, 2012<\/li>\n<\/ol>\n

    \u82f1\u8a9e\u8ad6\u6587<\/strong><\/h4>\n
      \n
    1. Ara MN., Hyodo M., Ohga N.,\u00a0Hida K.<\/u>, Harashima H.: Development of a novel DNA aptamer ligand against primary cultured tumor endothelial cells,\u00a0PLoS ONE<\/em><\/strong>, 7(12), e50174, 2012.<\/li>\n
    2. Takara K., Hiroto Hatakeyama H., Kibria G., Ohga N.,\u00a0Hida K.<\/u>, Harashima H.\uff1aSize-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise foruse in drug-resistant cancer therapy,\u00a0J Controlled Release<\/em><\/strong>, 162(1), 225-232, 2012<\/li>\n
    3. Osawa T., Ohga N. , Hida Y., Kitayama K., Akiyama K., Onodera Y., Fujie M., Shinohara N., Nonomura K., Shindoh M. ,\u00a0*Hida K.<\/u>: Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner,\u00a0Cancer Sci<\/em><\/strong>, 103(6), 1038-1044, 2012<\/li>\n
    4. Kawamoto T., Ohga N. , Akiyama K., Hirata N., Kitahara S, Maishi N., Osawa T., Yamamoto K., Kondoh M., Shindoh M., Hida Y.,\u00a0*Hida K.<\/u>: Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis,\u00a0PLoS ONE<\/em><\/strong>\u00a07(3) :e34045, 2012<\/li>\n
    5. Yamamoto K. , Ohga N., Hida Y., Maishi N., Kawamoto T., Kitayama K., Akiyama K., Osawa T., Kondoh M., Matsuda K., Onodera Y., Fujie M., Kaga K., Hirano S, Shinohara N., Shindoh M.,\u00a0*Hida K.<\/u>: Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells,\u00a0Br J Cancer<\/em><\/strong>, 106(6), 1214-1223, 2012<\/li>\n
    6. Maishi N., Ohga N., Hida Y.,\u3000 Akiyama K., Kitayama K., Osawa T., Onodera Y., Nonomura K., Shinohara N., Shindoh M.,\u00a0*Hida K<\/u>. : CXCR7 : A novel tumor endothelial marker in renal cell carcinoma,\u00a0Pathol Int,\u00a0<\/em><\/strong>62(5), 309-317, 2012<\/li>\n
    7. Ohga N., Ishikawa S., Maishi N., Akiyama K., Hida Y.,\u3000Kawamoto T., Sadamoto Y., Osawa T.,Yamamoto K., Kondoh M., Ohmura H., Shinohara N., Nonomura K., Shindoh M.,\u00a0*Hida K<\/u>.\uff1aHeterogeneity of Tumor Endothelial Cells: Comparison between Tumor Endothelial Cells Isolated from Highly Metastatic and Low Metastatic Tumors,\u00a0Am J Pathol<\/em><\/strong>, 180(3), 1294-1307, 2012<\/li>\n
    8. Akiyama K., Ohga N., Hida Y., Kawamoto T., Sadamoto Y., Ishikawa S., Maishi N., Akino T., Kondoh M., Matsuda A., Inoue N., Shindoh M. and\u00a0*Hida K<\/u>.: Tumor endothelial cells acquire drug resistance by MDR1 upregulation via VEGF signaling in tumor microenvironment,\u00a0Am J Pathol<\/em><\/strong>, 180(3), 1283-1293, 2012<\/li>\n<\/ol>\n

      \u62db\u5f85\u8b1b\u6f14<\/h4>\n
        \n
      1. Hida K.<\/u>\uff1a\u201cHeterogeneity of Tumor Endothelial Cells.\u201dThe 43rd International Symposium of The Princess Takamatsu Cancer Research Fund\u201cCancer Heterogeneity: Impact on Carcinogenesis, Cancer Stem Cell, Microenvironment, Diagnosis and Treatment\u201d 2012.11.15\uff08Tokyo, Japan\uff09<\/li>\n
      2. Hida K.<\/u>\uff1a\u201cAltered phenotype in endothelial cells in tumor microenvironment.\u201dThe 2nd International Symposium by JSPS Core-to-Core Program\u201cCooperative International Framework in TGF-\u03b2 Family Signaling\u201d 2012.10.30\uff08Tokyo, Japan\uff09<\/li>\n
      3. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c57\u56de\u65e5\u672c\u53e3\u8154\u5916\u79d1\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a\u30ef\u30fc\u30af\u30b7\u30e7\u30c3\u30d7\u300c\u304c\u3093\u6cbb\u7642\u6226\u7565\u3092\u76ee\u6307\u3057\u305f\u5148\u7aef\u7684\u304c\u3093\u7814\u7a76\u300d\u3001\u201c\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u3068\u8840\u7ba1\u65b0\u751f\u201d\u30012012.10.21\uff08\u6a2a\u6d5c\uff09<\/li>\n
      4. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c43\u56dePFA\u56fd\u969b\u6b6f\u5b66\u4f1a\u65e5\u672c\u90e8\u4f1a\u5e74\u6b21\u5927\u4f1a\uff0d\u30d4\u30a8\u30fc\u30eb\u30d5\u30a9\u30fc\u30b7\u30e3\u30eb\u30a2\u30ab\u30c7\u30df\u30fc\u56fd\u969b\u6b6f\u5b66\u4f1a\u65e5\u672c\u90e8\u4f1a\u3001\u201c\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3057\u305f\u65b0\u898f\u6297\u304c\u3093\u5264\u306e\u958b\u767a\u3092\u76ee\u6307\u3057\u3066\u201d\u30012012.9.29\uff08\u672d\u5e4c\uff09<\/li>\n
      5. Hida K.<\/u>\uff1a\u201cCrosstalk between tumor endothelial cells and tumor cells.\u201dThe 71st Annual Meeting of the Japanese Cancer Association, 2012.9.21\uff08Sapporo, Japan\uff09<\/li>\n
      6. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5e83\u5cf6\u5927\u5b66\u5973\u6027\u7814\u7a76\u8005\u30b9\u30ad\u30eb\u30a2\u30c3\u30d7\u4ea4\u6d41\u4f1a\u3001\u201c\u6bcd\u89aa\u3068\u3057\u3066\u3001PI\uff08Principle Investigator\uff09\u3068\u3057\u3066\u201d\u30012012.7.13\uff08\u5e83\u5cf6\uff09<\/li>\n
      7. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c28\u56de\u65e5\u672cDDS\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u3001\u201c\u304c\u3093\u306e\u6d78\u6f64\u8ee2\u79fb\u3068\u8840\u7ba1\u65b0\u751f\u201d\u30012012.7.4\uff08\u672d\u5e4c\uff09<\/li>\n
      8. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c101\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30b3\u30f3\u30d1\u30cb\u30aa\u30f3\u30df\u30fc\u30c6\u30a3\u30f3\u30b0\uff17\u300c\u53e3\u8154\u764c\u306e\u60aa\u6027\u5f62\u8cea\u306e\u767a\u73fe\u306b\u95a2\u3059\u308b\u6a4b\u6e21\u3057\u7814\u7a76\u3068\u5206\u5b50\u6a19\u7684\u6cbb\u7642\u3078\u306e\u5fdc\u7528\u300d\u3001\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u3068\u8ee2\u79fb\u3068\u306e\u95a2\u9023\u201d\uff0c2012.4.28\uff08\u6771\u4eac\uff09<\/li>\n
      9. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u5343\u91cc\u30e9\u30a4\u30d5\u30b5\u30a4\u30a8\u30f3\u30b9\u30bb\u30df\u30ca\u30fc\u300c\u304c\u3093\u306e\u6d78\u6f64\u30fb\u8ee2\u79fb\u3068\u5fae\u5c0f\u74b0\u5883\u300d\uff0c\u201c\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u6297\u304c\u3093\u5264\u62b5\u6297\u6027\u201d\uff0c2012.2.24\uff08\u5927\u962a\uff09<\/li>\n
      10. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u7b2c30\u56de\u65e5\u672c\u53e3\u8154\u816b\u760d\u5b66\u4f1a\u5b66\u8853\u5927\u4f1a\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u53e3\u8154\u764c\u306e\u6d78\u6f64\uff0d\u30de\u30af\u30ed\u30fb\u30df\u30af\u30ed\u30fb\u30e2\u30ec\u30ad\u30e5\u30e9\u30fc\u300d\uff0c\u201c\u304c\u3093\u306e\u6d78\u6f64\u8ee2\u79fb\u3068\u8840\u7ba1\u65b0\u751f\u201d\uff0c2012.1.26\uff08\u5927\u5bae\uff09<\/li>\n
      11. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u516c\u958b\u30b7\u30f3\u30dd\u30b8\u30a6\u30e0\u300c\u8840\u7ba1\u3092\u6a19\u7684\u3068\u3059\u308b\u9769\u65b0\u7684\u533b\u85ac\u5206\u5b50\u9001\u9054\u6cd5\u306e\u57fa\u76e4\u6280\u8853\u306e\u78ba\u7acb\u300d\uff0c\u201c\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u7570\u6027\u306e\u89e3\u660e\u201d\uff0c2012.1.12\uff08\u672d\u5e4c\uff09<\/li>\n<\/ol>\n

        \u56fd\u969b\u5b66\u4f1a\u767a\u8868<\/strong><\/h4>\n
          \n
        1. Hida K.<\/u>\uff1aFinding Specific Anti-cancer Drugs Using Human Tumor Vascular Cells. 7th Annual International Partnering Conference \u201cBIO-Europe Spring 201\u201d, 2012.3.11-13, Barcelona, Spain<\/li>\n
        2. Hida K.<\/u>, Omura H., Akiyama K., Ohga N., Maishi N., Kawamoto T., Kondoh M., Hida Y.\uff1a Characterization of stem-like tumor endothelial cells, The 20th annual Meeting of the Japanese Vascular Biology and MedicineOrganization, The 10th Korea-Japan Joint Symposium on Vascular Biology, 2012.12. 5-7, Tokushima, Japan<\/li>\n
        3. Ohga N., Yamamoto K., Hida Y., Maishi N., Kawamoto T., Shindoh M.,\u00a0Hida K.<\/u>\u00a0: Biglycan is an autocrine angiogenic factor of tumor endothelial cells\uff0cThe 20th annual Meeting of the Japanese Vascular Biology and MedicineOrganization, The 10th Korea-Japan Joint Symposium on Vascular Biology, 2012.12. 5-7, Tokushima, Japan<\/li>\n
        4. Akiyama K., Ohga N., Hida Y., Maishi N., Alam Mohammad Towfik., Kawamoto T., Omura H., Yamada K., Torii C., Sakamoto H. Matsuda A.,\u00a0Hida K.<\/u>:Tumor endothelium acquires drugresistance by MDR1\/P-gp upregulationand metronomic chemotherapycombined with P-gp inhibitor enhancesantiangiogenic activity in vivo\uff0cThe 20th annual Meeting of the Japanese Vascular Biology and MedicineOrganization, The 10th Korea-Japan Joint Symposium on Vascular Biology, 2012.12. 5-7, Tokushima, Japan<\/li>\n
        5. Kondoh M., Ohga N., Akiyama K., Maishi N., Kawamoto T., Hida Y., Shindoh M.,\u00a0Hida K.<\/u>: Hypoxia induces angiogenic factors andaneuploidy in micirovascular endothelialcells\uff0cThe 20th annual Meeting of the Japanese Vascular Biology and MedicineOrganization, The 10th Korea-Japan Joint Symposium on Vascular Biology, 2012.12. 5-7, Tokushima, Japan<\/li>\n
        6. Hida K.<\/u>\uff1a\u201cHeterogeneity of Tumor Endothelial Cells.\u201d The 43rd International Symposium of The Princess Takamatsu Cancer Research Fund\u201cCancer Heterogeneity: Impact on Carcinogenesis, Cancer Stem Cell, Microenvironment, Diagnosis and Treatment\u201d 2012.11.15\uff08Tokyo, Japan\uff09<\/li>\n
        7. Hida K.<\/u>\uff1a\u201cAltered phenotype in endothelial cells in tumor microenvironment.\u201dThe 2nd International Symposium by JSPS Core-to-Core Program\u201cCooperative International Framework in TGF-\u03b2 Family Signaling\u201d 2012.10.30\uff08Tokyo, Japan\uff09<\/li>\n
        8. Yamamoto K., Ohga N., Hida Y., Maishi N., Kawamoto T., Kitayama K., Akiyama K., Osawa T., Kondoh M., Kaga K., Shinohara N., Shindoh M., Hirano S.,\u00a0Hida K<\/u>. :Biglycan is a specific marker and an autocrine angiogenic factor of tumor endothelial cells, the 17th International Vascular Biology Meeting, 2012.6.5, Wiesbaden, Germany<\/li>\n
        9. Hida K<\/u>., Akiyama K., Ohga N., Hida Y., Kawamoto T., Sadamoto Y., Maishi N., Akino T., Kondoh M., Shindoh M.: Tumor endothelial cell s acquire drug resistance by MDR1 upregulation, the 17th International Vascular Biology Meeting, 2012.6.4, Wiesbaden, Germany<\/li>\n
        10. Kawamoto T., Ohga N., Akiyama K., Hirata N., Kitahara S., Maishi N., Osawa T., Yamamoto K., Kondoh M., Shindoh M., Hida Y.,Hida K<\/u>.: Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis,the 17th International Vascular Biology Meeting, 2012.6.4, Wiesbaden, Germany<\/li>\n
        11. Maishi N., Ohba Y., Yamamoto K., Ohga N., Hamada J., Akiyama K., Kawamoto T., Osawa T., Kondoh M., Ohmura H., Shindoh M., Hida Y.,\u00a0Hida K<\/u>. : Contribution of tumor endothelial cells to tumor metastasis, the 17th International Vascular Biology Meeting, 2012.6.2, Wiesbaden, Germany<\/li>\n
        12. Yamamoto K., Ohga N., Hida Y., Maishi N., Kawamoto T., Kitayama K., Akiyama K., Osawa T., Kondoh M., Kaga K., Hirano S., Shinohara N., Shindoh M.,\u00a0Hida K<\/u>. : Biglycan is a specific marker and an autocrine angiogenic factor of tumor endothelial cells, AACR ANNUAL MEETING 2012, 2012.4.2, Chicago, Illinois<\/li>\n
        13. Osawa T., Ohga N., Hida Y., Kitayama K., Yamamoto Y., Kawamoto T., Maishi N., Kondoh M., Akiyama K., Onodera Y., Shinohara N., Nonomura K., Shindoh M.,\u00a0Hida K<\/u>. : The role of lysyl oxidase on proangiogenic phenotypes of tumor endothelial cells, AACR ANNUAL MEETING 2012, 2012.4.2, Chicago, Illinois<\/li>\n
        14. Akiyama K., Ohga N., Hida Y., Kawamoto T., Sadamoto Y., Ishikawa S., Maishi N., Tomoshige A., Kondoh M., Matsuda A., Inoue N., Shindoh M.,\u00a0Hida K<\/u>. : Tumor endothelial cells acquire drug resistance by MDR1 upregulation via VEGF signaling in tumor microenvironment, AACR ANNUAL MEETING 2012, 2012.4.2, Chicago, Illinois<\/li>\n
        15. Kawamoto T., Ohga N., Akiyama K., Hirata N., Maishi N., Osawa T., Yamamoto K., Kondoh M., Shindoh M., Hida Y.,\u00a0Hida K<\/u>.\uff1aTumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis, AACR ANNUAL MEETING 2012, 2012.4.2, Chicago, Illinois<\/li>\n<\/ol>\n

          \u56fd\u5185\u5b66\u4f1a\u767a\u8868<\/strong><\/h4>\n
            \n
          1. \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aCrosstalk between tumor endothelial cells and tumor cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
          2. \u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d,\u3000\u79cb\u5c71\u5ee3\u8f14\uff0c\u5e73\u7530\u5c1a\u4e5f\uff0c\u5317\u539f\u79c0\u6cbb\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Tumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
          3. \u5927\u8cc0\u5247\u5b5d\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c \u5e73\u91ce\u3000\u8061, \u7be0\u539f\u4fe1\u96c4\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u00a0*<\/u>\u6a0b\u7530\u4eac\u5b50<\/u>\uff0c: Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
          4. \u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5317\u5c71\u548c\u5b50\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u7be0\u539f\u4fe1\u96c4\uff0c\u91ce\u3005\u6751\u514b\u4e5f\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>\u00a0: The role of Lysyl oxidase on proangiogenic phenotypes of tumor endothelial cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
          5. \u9593\u77f3\u5948\u6e56\uff0c\u5927\u5834\u96c4\u4ecb\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u6d5c\u7530\u6df3\u4e00\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6751\u3000\u77b3\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: The role of tumor endothelial cells in tumor metastasis, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
          6. \u5927\u6751\u3000\u77b3\uff0c\u79cb\u5c71\u5ee3\u8f14\uff0c\u5927\u8cc0\u5247\u5b5d\uff0c\u9593\u77f3\u5948\u6e56\uff0c\u6a0b\u7530\u6cf0\u6d69\uff0c\u5ddd\u672c\u6cf0\u8f14\uff0c\u8fd1\u85e4\u7f8e\u5f25\u5b50\uff0c\u5927\u6fa4\u5d07\u5b8f\uff0c\u5c71\u672c\u548c\u5e78\uff0c\u98ef\u7530\u9806\u4e00\u90ce\uff0c\u9032\u85e4\u6b63\u4fe1\uff0c\u6a0b\u7530\u4eac\u5b50<\/u>: Characterization of Aldehyde dehydrogenase(ALDH) positive tumor endothelial cells, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.21\uff08\u672d\u5e4c\uff09<\/li>\n
          7. \u571f\u5c4b\u90a6\u5f66, \u5927\u6fa4\u5d07\u5b8f, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5317\u5c71\u548c\u5b50, \u79cb\u5c71\u5ee3\u8f14, \u5c0f\u91ce\u5bfa\u96c4\u4e00\u90ce, \u7be0\u539f\u4fe1\u96c4, \u85e4\u6c5f\u00a0 \u5b66, \u9032\u85e4\u6b63\u4fe1, \u91ce\u3005\u6751\u514b\u4e5f, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u30d7\u30ed\u30b9\u30bf\u30b5\u30a4\u30af\u30ea\u30f3\u53d7\u5bb9\u4f53\u306f\u8840\u7ba1\u65b0\u751f\u3092\u30aa\u30fc\u30c8\u30af\u30e9\u30a4\u30f3\u306b\u4fc3\u9032\u3059\u308b, \u7b2c71\u56de\u65e5\u672c\u764c\u5b66\u4f1a\u5b66\u8853\u7dcf\u4f1a, 2012.9.19\uff08\u672d\u5e4c\uff09<\/li>\n
          8. \u5ddd\u672c\u6cf0\u8f14, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u5e73\u7530\u5c1a\u4e5f, \u5317\u539f\u79c0\u6cbb, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-Derived Microvesicles Induce Proangiogenic Phenotype in Endothelial Cells via Endocytosis, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
          9. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u5c71\u672c\u548c\u5e78, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6751\u00a0 \u77b3, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u308f\u308a, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
          10. \u5927\u8cc0\u5247\u5b5d, \u5c71\u672c\u548c\u5e78, \u6a0b\u7530\u6cf0\u6d69, \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aBiglycan is an autocrine angiogenic factor of tumour endothelial cells, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
          11. \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5185\u4f4e\u9178\u7d20\u74b0\u5883\u3068\u816b\u760d\u8840\u7ba1\u5185\u76ae\u306e\u7570\u5e38\u6027\u306e\u95a2\u9023, \u7b2c92\u56de\u5317\u6d77\u9053\u533b\u5b66\u5927\u4f1a\uff08\u7b2c106\u56de\u5317\u6d77\u9053\u764c\u8ac7\u8a71\u4f1a\u4f8b\u4f1a\u3000\u816b\u760d\u7cfb\u5206\u79d1\u4f1a\uff09, 2012.9.8\uff08\u672d\u5e4c\uff09<\/li>\n
          12. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u9593\u77f3\u5948\u6e56, \u79cb\u5c71\u5ee3\u8f14, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6751\u00a0 \u77b3, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u306e\u7279\u6027\u89e3\u6790, \u7b2c23\u56de\u65e5\u672c\u81e8\u5e8a\u53e3\u8154\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a\u30fb\u5b66\u8853\u5927\u4f1a, 2012.8.31\uff08\u6771\u4eac\uff09<\/li>\n
          13. \u9593\u77f3\u5948\u6e56, \u5927\u5834\u96c4\u4ecb, \u5c71\u672c\u548c\u5e78, \u5927\u8cc0\u5247\u5b5d, \u6d5c\u7530\u6df3\u4e00, \u79cb\u5c71\u5ee3\u8f14, \u5ddd\u672c\u6cf0\u8f14, \u5927\u6fa4\u5d07\u5b8f, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6751\u00a0 \u77b3, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u304c\u3093\u8ee2\u79fb\u3078\u306e\u95a2\u308f\u308a, \u7b2c21\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2012.7.12\uff08\u5e83\u5cf6\uff09<\/li>\n
          14. \u5927\u6751\u77b3, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u5ddd\u672c\u6cf0\u8f14, \u98ef\u7530\u9806\u4e00\u90ce, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306b\u304a\u3051\u308bALDH\u306e\u767a\u73fe\u89e3\u6790\u3068ALDH\u9ad8\u6d3b\u6027\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7279\u6027\u89e3\u6790, \u7b2c21\u56de\u65e5\u672c\u304c\u3093\u8ee2\u79fb\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a\u30fb\u7dcf\u4f1a, 2012.7.12\uff08\u5e83\u5cf6\uff09<\/li>\n
          15. \u5ddd\u672c\u6cf0\u8f14, \u5927\u8cc0\u5247\u5b5d, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u6cf0\u6d69, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1aTumor-derived microvesicles induce proangiogenic phenotype in endothelial cells via endocytosis, \u7b2c28\u56de\u65e5\u672cDDS\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.7.4\uff08\u672d\u5e4c\uff09<\/li>\n
          16. \u5927\u8cc0\u5247\u5b5d, \u77f3\u5ddd\u4fee\u5e73, \u6a0b\u7530\u6cf0\u6d69, \u79cb\u5c71\u5ee3\u8f14, \u9593\u77f3\u5948\u6e56, \u5ddd\u672c\u6cf0\u8f14, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u8ee2\u79fb\u80fd\u306e\u7570\u306a\u308b\u816b\u760d\u7531\u6765\u306e\u8840\u7ba1\u5185\u76ae\u306e\u7279\u6027\u89e3\u6790, \u7b2c28\u56de\u65e5\u672cDDS\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.7.3\uff08\u672d\u5e4c\uff09<\/li>\n
          17. \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5b9a\u672c\u572d\u5f18, \u77f3\u5ddd\u4fee\u5e73, \u9593\u77f3\u5948\u6e56, \u79cb\u91ce\u6587\u81e3, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u677e\u7530\u00a0 \u5f69, \u4e95\u4e0a\u8fb2\u592b\u7537, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308bVEGF\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u305fMDR1\u306e\u767a\u73fe\u4ea2\u9032\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066, \u7b2c66\u56de\u65e5\u672c\u53e3\u8154\u79d1\u5b66\u4f1a\u5b66\u8853\u96c6\u4f1a, 2012.5.18\uff08\u5e83\u5cf6\uff09<\/li>\n
          18. \u79cb\u5c71\u5ee3\u8f14, \u5927\u8cc0\u5247\u5b5d, \u6a0b\u7530\u6cf0\u6d69, \u5ddd\u672c\u6cf0\u8f14, \u5b9a\u672c\u572d\u5f18, \u77f3\u5ddd\u4fee\u5e73, \u8fd1\u85e4\u7f8e\u5f25\u5b50, \u9593\u77f3\u5948\u6e56, \u5927\u6fa4\u5d07\u5b8f, \u5c71\u672c\u548c\u5e78, \u9032\u85e4\u6b63\u4fe1, \u6a0b\u7530\u4eac\u5b50<\/u>\uff1a\u816b\u760d\u5fae\u5c0f\u74b0\u5883\u306b\u304a\u3051\u308bVEGF\u30b7\u30b0\u30ca\u30eb\u3092\u4ecb\u3057\u305fMDR1\u306e\u767a\u73fe\u4ea2\u9032\u306b\u3088\u308b\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u85ac\u5264\u62b5\u6297\u6027\u7372\u5f97\u306b\u3064\u3044\u3066, \u7b2c101\u56de\u65e5\u672c\u75c5\u7406\u5b66\u4f1a\u7dcf\u4f1a, 2012.4.28\uff08\u6771\u4eac\uff09<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

            \u7dcf\u8aac\u30fb\u8457\u66f8\uff08\u65e5\u672c\u8a9e\uff09 \u6a0b\u7530\u4eac\u5b50\u3001\u5927\u8cc0\u5247\u5b5d\u3001\u79cb\u5c71\u5ee3\u8f14\u3001\u9593\u77f3\u5948\u6e56\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u3068\u764c\u306e\u60aa\u6027\u5316\u3068\u306e\u95a2\u9023\u3001\u65e5\u672c\u53e3\u8154\u816b\u760d\u5b66\u4f1a\u8a8c\u300124(3)\u300188-94\u30012012 \u6a0b\u7530\u4eac\u5b50\uff1a\u304c\u3093\u5fae\u5c0f\u74b0\u5883\u3068\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u3001\u201cDrug Delivery System\u201d\u3001\u7279\u96c6\uff62\u57fa\u790e\u304b\u3089\u62d3\u304fDDS\u5275\u85ac\u30d5\u30ed\u30f3\u30c6\u30a3\u30a2\uff63\u65e5\u672cDDS\u5b66\u4f1a\u300127(1)\u300134-39\u30012012 \u6a0b\u7530\u4eac\u5b50\uff1a\u816b\u760d\u8840\u7ba1\u5185\u76ae\u7d30\u80de\u306e\u7570\u5e38\u6027\u3001\u300c\u751f\u5316\u5b66\u300d\u3001\u793e\u56e3\u6cd5\u4eba\u65e5\u672c…\u7d9a\u304d\u3092\u8aad\u3080<\/a><\/p>\n","protected":false},"author":3,"featured_media":0,"parent":18,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"publications.php","meta":{"footnotes":""},"class_list":["post-175","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/175","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/comments?post=175"}],"version-history":[{"count":7,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/175\/revisions"}],"predecessor-version":[{"id":875,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/175\/revisions\/875"}],"up":[{"embeddable":true,"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/pages\/18"}],"wp:attachment":[{"href":"https:\/\/www.den.hokudai.ac.jp\/vascular-biol-pathol\/wp-json\/wp\/v2\/media?parent=175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}